Daniel Spratt, MD, of University Hospitals Seidman Cancer Center, reviews his recent study on the safety and efficacy of relugolix plus radiotherapy (RT) in patients with localized or advanced prostate cancer, including key findings and implications for clinical practice.
Dr. Spratt also comments on the evolving role of RT in combination with novel therapeutic agents.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.